Get started
JOHNSON & JOHNSONJOHNSON & JOHNSONJOHNSON & JOHNSON

JOHNSON & JOHNSON

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

JNJ trade ideas

JNJ BO W4 running flat; ext W5 of V ends in 2023 bef recessionIn the bigger picture in this weekly chart, JNJ BO of the big multi-year red upchannel & retested it several times in 2021 when JNJ was making wave 4 of V which is a running flat consolidation lasting the whole of 2021 bottoming in 29 Nov2021. Notice that the bigger wave IV is an expanded flat (megaphone pattern) bottoming in covid low. Now it has completed wave 4 of V & has successfully broke out of this wave 4 running flat consolidation breaking the 174 resistance. First attempt was in August of 2021, a false BO (bulltrap) before it crash down to complete wave 4 & also again retest the big red upper upchannel for the 5th time. (It was retested a total of 7 times) The whole wave V was pretty much in the form of an upchannel. JNJ now doing the final wave 5 of V. This looks like an extended wave 5 which will end sometime in 2023 before recession. JNJ belongs to XLP staples group & has recently been outperforming SPX as it is a defensive stock in times of market uncertainty. Not trading advice
NYSE:JNJLong
by xtremerider8
$JNJ to make new ATH's$JNJ looks primed and ready to make new all-time highs this week. JNJ is in an ascending channel and based on RSI staying above 50 combined with MACD building and not near its relative "max" (about 4.44), this stock looks like it has legs. I think it is about to break through resistance relatively easily. With this risky, volatile, day-to-day market, healthcare will be one of the sectors to hide out in and have relative stability and more potential for upside. A good defensive place to be that can be a lucrative trade/investment. JNJ is the best-in-breed, blue-chip with a solid diversified portfolio and potential for capital appreciation alongside a 2.40% dividend yield. Healthcare is going to be a killer sector to be in if you have about a 5-year time horizon. During tightening cycles, tech, energy, and utilities do well, but I do see healthcare being one of the need-to-be in sectors going forward.
NYSE:JNJLong
by EBITDAtiger
Johnson and Johnson at Key Resistance? Johnson and Johnson - Short Term - We look to Sell at 176.93 (stop at 178.95) Previous resistance located at 176.00. We look to sell rallies. This provides an excellent risk/reward opportunity to fade the current bullish move. Although the anticipated move lower is corrective, it does offer ample risk/reward today. Our profit targets will be 172.09 and 168.20 Resistance: 176.00 / 180.00 / 200.00 Support: 170.00 / 165.00 / 155.00 Disclaimer โ€“ Saxo Bank Group. Please be reminded โ€“ you alone are responsible for your trading โ€“ both gains and losses. There is a very high degree of risk involved in trading . The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading โ€“ both gains and losses.
NYSE:JNJShort
by Saxo
Johnson and Johnson loosing ground. JNJImmediate targets at 165, 156, 149. Invalidation at 194. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
NYSE:JNJShort
by Rykin_Capital
Johnson & Johnson | Fundamental Analysis | LONG SETUP โšก๏ธFor much of the previous decade, the stock of diversified healthcare behemoth Johnson & Johnson has consistently delivered market returns (if you count dividends as part of total return on equity). Investors flocked to this company because of its solid balance sheet, its status as a dividend aristocrat, and its unique ability to consistently bring new blockbuster pharmaceutical products to market in a timely manner. Since the beginning of this decade, however, J&J stock has largely underperformed the broader markets. The stock has lost its luster recently because of the baby powder litigation, the lack of enthusiasm among investors for the $30 billion acquisition of Actelion, the maker of pulmonary arterial hypertension drugs, its high valuation, and the relatively low sales of its COVID-19 vaccine. Will J&J stock be able to return to its previous market successes or should investors move to a more favorable environment? Here's a look at both sides of the question. 1. J&J may be one of the top stocks in healthcare today, but this $444 billion titan is about to undergo some major changes that could lead to a decline in its performance. According to a Nov. 12 announcement, the company plans to split into two businesses over the next 24 months. One of the new businesses will focus on consumer health products and the other on the development and commercialization of pharmaceuticals and medical devices. The transition will be one of the largest in the company's 135-year history, and it will entail reshuffles in all areas, including senior management. This means that serious risks loom on the horizon that shareholders have not yet had to deal with. Splitting the business in two may turn out for the best, but it's important to remember that things haven't been going in the right direction for some time. Over the past five years, quarterly revenue has grown by only 28.9 percent, while quarterly profit margins have fallen by 25.4 percent. Similarly, quarterly net income is down 3.85% and quarterly free cash flow (FCF) is down more than 19% over the same period. There is no guarantee that the separation will solve these problems. In addition to the uncertainties associated with the separation, the company also faces new hurdles regarding revenue from the coronavirus vaccine, which is expected to bring in $2.5 billion in 2021. On Dec. 16, the Centers for Disease Control and Prevention issued a recommendation that the company's vaccine should not be used if vaccines from competitors such as Pfizer are available. The recommendation comes amid ongoing concerns about the J&J vaccine's poor efficacy and its ability to cause rare and life-threatening complications in some people. Therefore, this is a particularly risky time to invest in J&J stock. Time will tell if the company can gracefully survive its breakup. 2. Wall Street has not been particularly receptive to J&J's proposed separation and for good reason. After all, the company's health care division contains several iconic brands, such as Benadryl and Tylenol, which are proven cash cows. Wall Street's fears about this separation, however, may have been exaggerated. As evidence, Pfizer recently went through a slimming process, separating its legacy products business without any adverse consequences. And J&J, for its part, seems more than capable of pulling off the same maneuver without any major hitches. This is evidenced by a wide range of fast-growing pharmaceutical products, such as the multiple myeloma drug Darzalex, the immune-mediated inflammatory disease drug Stelara, and the plaque psoriasis drug Tremfya. It was these three key products that drove the company's pharmaceutical segment in the third quarter of 2021, up 13.8% from a year ago, excluding acquisitions and sales. Moreover, J&J is one of the best in the business at launching new pharmaceutical products for areas with large unmet medical needs. In fact, this separation should allow the company's pharmaceutical division to shine from a top-line perspective. And that's a big plus for growth-oriented investors. Income investors may be concerned about the potential impact on the company's much-desired dividend. Fortunately, J&J management has already said that future dividend payments should remain about the same as the current quarterly distribution after the split. Overall, J&J stock seems poised to turn into a top play for growth and earnings after the upcoming split.
NYSE:JNJLong
by FOREXN1
JNJ Formed a nice Double Bottom patternHi everyone, $JNJ formed a nice Double Bottom pattern on Daily timeframe . The price hit twice the strong support formed at around 155 price level. It recently broke the resistance level at 167 and now it is ready to test it again as a support level. If tested successfully it offers a really nice buy setup. If you like the idea, do not forget to support with a like and follow. * ๐—ง๐—ต๐—ฒ ๐—ถ๐—ป๐—ณ๐—ผ๐—ฟ๐—บ๐—ฎ๐˜๐—ถ๐—ผ๐—ป ๐—ฎ๐—ป๐—ฑ ๐—ฎ๐—ป๐—ฎ๐—น๐˜†๐˜€๐—ถ๐˜€ ๐˜€๐—ต๐—ฎ๐—ฟ๐—ฒ๐—ฑ ๐—ถ๐—ป ๐˜๐—ต๐—ถ๐˜€ ๐—ฝ๐—ผ๐˜€๐˜ ๐—ถ๐˜€ ๐—ป๐—ผ๐˜ ๐—ณ๐—ถ๐—ป๐—ฎ๐—ป๐—ฐ๐—ถ๐—ฎ๐—น ๐—ฎ๐—ฑ๐˜ƒ๐—ถ๐—ฐ๐—ฒ ๐—ฎ๐—ป๐—ฑ ๐—ถ๐˜€ ๐—ณ๐—ผ๐—ฟ ๐—ฒ๐—ฑ๐˜‚๐—ฐ๐—ฎ๐˜๐—ถ๐—ผ๐—ป๐—ฎ๐—น ๐—ฝ๐˜‚๐—ฟ๐—ฝ๐—ผ๐˜€๐—ฒ ๐—ผ๐—ป๐—น๐˜†! ๐—”๐—น๐˜„๐—ฎ๐˜†๐˜€ ๐—ฐ๐—ผ๐—ป๐—ฑ๐˜‚๐—ฐ๐˜ ๐˜†๐—ผ๐˜‚๐—ฟ ๐—ผ๐˜„๐—ป ๐—ฎ๐—ป๐—ฎ๐—น๐˜†๐˜€๐—ถ๐˜€ ๐—ฎ๐—ป๐—ฑ ๐—ฟ๐—ฒ๐˜€๐—ฒ๐—ฎ๐—ฟ๐—ฐ๐—ต.
NYSE:JNJLong
by preduta